Transforming Autoimmune Treatment: Where Precision Meets Possibility
Driving an immune reset through the targeted depletion of pathogenic cells




The next wave of precision immunotherapies
Hillstar Bio is shaping a new era in autoimmune disease treatment through precision immunology. We selectively target and deplete pathogenic immune cells while sparing healthy ones, offering the potential for durable relief via an immune reset for patients with autoimmune conditions.
Unlike traditional therapies that broadly suppress the immune system, our targeted approach addresses specific disease mechanisms by eliminating pathogenic cells, reducing the risks associated with chronic broad immunosuppression while potentially delivering deeper, more durable responses with less frequent dosing compared to existing therapies.
We combine scientific expertise in antibody engineering with a disciplined approach, building upon validated modalities and disease-specific genetic markers to de-risk development while identifying patient populations most likely to benefit from our therapies, moving beyond the one-size-fits-all approach of current autoimmune treatments.

Delivering precision therapies that drive durable disease remission
We're building a pipeline of precision immunotherapies targeting specific immune-cell subsets in autoimmune diseases. These therapies have the potential to offer an immune reset rather than chronic symptom management, providing flexibility in selecting the optimal discovery approaches for each target, free from the constraints of platform limitations.
HSB-101
Our lead program depletes TRBV9+ T cells in axial spondyloarthritis (AxSpA) and other related HLA-B27-mediated immune and inflammatory conditions. By binding to specific pathogenic cells, our antibody therapeutic offers a selective approach to immune modulation that elevates the patient experience with the potential for an immune reset. The Phase 1 HSB-001 is anticipated to initiate in 2026.
Undisclosed
Programs
An accomplished team dedicated to advancing precision immunotherapy
Hillstar Bio brings together leading experts in antibody engineering, immunology, and clinical development, and is backed by prominent venture capital firms.
Our leadership team combines deep understanding of immune-cell biology with a proven track record of discovering and developing breakthrough therapies for patients with autoimmune diseases. We're emboldened by science and driven by unmet patient needs, with a shared commitment to transforming autoimmune care through advanced precision immunology approaches that go beyond symptom management to potentially reset the immune system and address the underlying mechanisms of disease.
The latest news from Hillstar Bio
Become a part of Hillstar Bio
Join us in our mission to transform autoimmune treatment through precision immunology. We're seeking talented individuals who are inspired by the possibility of delivering next-generation precision immunotherapies to patients still struggling with autoimmune diseases.
At Hillstar Bio, you'll be part of a team that values scientific rigor, innovation, and a focus on patients. We offer a collaborative environment where your contributions can directly impact our ability to deliver transformative medicines with the potential to reset the immune system.


